Sort   by:  
 Page size 
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
UnknownSociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry.
Not available
S-EPMC9535223 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownEnvironmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study.
Not available
S-EPMC9313519 | biostudies-literature
UnknownHeight and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants.
Not available
S-EPMC7658740 | biostudies-literature
UnknownHeterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight.
Not available
S-EPMC7943191 | biostudies-literature
UnknownGeneral and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7·5 million participants.
Not available
S-EPMC7616775 | biostudies-literature
UnknownDiminishing benefits of urban living for children and adolescents' growth and development.
Not available
S-EPMC10060164 | biostudies-literature
UnknownWorldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
Not available
S-EPMC7615769 | biostudies-literature
Sort   by:  
 Page size